Trevena (TRVN): Commercial Countdown Begins - HCWainwright

March 8, 2018 7:30 AM EST
Get Alerts TRVN Hot Sheet
Price: $0.25 +4.17%

Rating Summary:
    9 Buy, 4 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 40 | New: 22
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Trevena (NASDAQ: TRVN) and raised his price target to $7 from $5 looking ahead 8 months to the PDUFA date of November 2, 2018. In January 2018, Trevena announced that the FDA accepted its NDA for OLINVO (IV oliceridine), the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief.

The analyst stated "given that DEA scheduling of controlled substances (management fully expects Schedule II for OLINVO) is normally due within 90 days of approval, management has guided to a 1Q19 commercial launch in the U.S. As we continue the countdown to critical near-term value inflection points for TRVN shares, we affirm our Buy rating and raise our PT".

For an analyst ratings summary and ratings history on Trevena click here. For more ratings news on Trevena click here.

Shares of Trevena closed at $1.88 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

PDUFA, H.C. Wainwright, Ed Arce, FDA